Close Menu

NEW YORK and SAN FRANCISCO – Illumina and Genomics England announced Monday a new agreement to sequence up to 300,000 genomes over five years.

Under the terms of the agreement, Illumina will deliver up to 300,000 "whole genome equivalents," with an option to increase the number to 500,000. Initially, samples from NHS patients in England with known rare diseases and cancer types will be eligible for whole-genome sequencing (WGS) to support diagnosis and inform treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.

The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.

The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.

Researchers have sequenced the genome of "the Methuselah of freshwater fish."

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.